| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Zena and Michael A. Wiener Cardiovascular Institute and the Department of Medicine,* and the Immunobiology Center, Mount Sinai School of Medicine, New York, New York; the Center for Cellular and Molecular Cardiology,|| University of Rochester, Rochester, New York; the Department of Immunology, Schering-Plough Research Institute, Kenilworth, New Jersey; the Department of Pharmacology, Laboratory for Molecular Pharmacology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark; and the Departments of Medicine and Pathology,¶ University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
Chemokines have been implicated in the pathogenesis of a wide variety of diseases. This report describes the generation of transgenic mice that conditionally express M3, a herpesvirus protein that binds and inhibits chemokines. In response to doxycycline, M3 expression was induced in a variety of tissues and M3 was detectable in the blood by Western blotting. No gross or histological abnormalities were seen in mice expressing M3. To determine whether M3 expression could modify a significant pathophysiological response, we examined its effect on the development of intimal hyperplasia in response to femoral arterial injury. Intimal hyperplasia is thought to play a critical role in the development of restenosis after percutaneous transluminal coronary angioplasty and in the progression of atherosclerosis. Induction of M3 expression resulted in a 67% reduction in intimal area and a 68% reduction in intimal/medial ratio after femoral artery injury. These data support a role for chemokines in regulating intimal hyperplasia and suggest that M3 may be effective in attenuating this process. This transgenic mouse model should be a valuable tool for investigating the role of chemokines in a variety of pathological states.
This article has been cited by other articles:
 |
|
 |
|
  A. P. Martin, M. G. Grisotto, C. Canasto-Chibuque, S. L. Kunkel, J. S. Bromberg, G. C. Furtado, and S. A. Lira Islet Expression of M3 Uncovers a Key Role for Chemokines in the Development and Recruitment of Diabetogenic Cells in NOD Mice Diabetes, February 1, 2008; 57(2): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Alexander-Brett and D. H. Fremont Dual GPCR and GAG mimicry by the M3 chemokine decoy receptor J. Exp. Med., December 24, 2007; 204(13): 3157 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. White, D. F. Meoli, R. F. Swarthout, D. Y. Kallop, I. I. Galaria, J. L. Harvey, C. M. Miller, B. C. Blaxall, C. M. Hall, R. A. Pierce, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L583 - L590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Martin, C. Canasto-Chibuque, L. Shang, B. J. Rollins, and S. A. Lira The Chemokine Decoy Receptor M3 Blocks CC Chemokine Ligand 2 and CXC Chemokine Ligand 13 Function In Vivo J. Immunol., November 15, 2006; 177(10): 7296 - 7302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Charo and M. B. Taubman Chemokines in the Pathogenesis of Vascular Disease Circ. Res., October 29, 2004; 95(9): 858 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lucas and G. McFadden Secreted Immunomodulatory Viral Proteins as Novel Biotherapeutics J. Immunol., October 15, 2004; 173(8): 4765 - 4774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
